Physician profile
Iris Burns
NPI 1205436839
$1,713.72
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $314 · 2023: $220 · 2024: $168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $395.28 | 2021-2024 | Evenity, Prolia |
| Boston Scientific Corporation | $335.89 | 2021-2023 | Ranger, Jetstream Sc, Imager II |
| Astrazeneca Pharmaceuticals Lp | $314.71 | 2021 | |
| Janssen Pharmaceuticals, INC | $164.78 | 2021-2022 | |
| Pfizer INC. | $155.90 | 2021 | |
| Novo Nordisk INC | $63.78 | 2021 | |
| Glaxosmithkline, LLC. | $57.01 | 2021-2022 | |
| Mannkind Corporation | $34.58 | 2021 | |
| Abbvie INC. | $25.83 | 2021 | |
| Lilly USA, LLC | $24.44 | 2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $21.54 | 2021 | |
| Xeris Pharmaceuticals, INC. | $20.44 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.20 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.94 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $13.76 | 2021 | |
| Radius Health, INC. | $13.23 | 2021 | |
| Masimo Corporation | $13.12 | 2022 | |
| Esperion Therapeutics, INC. | $13.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iris Burns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.